RxDoctor Payments Data

Laurel Duba, APRN

Primary Care · Lincoln, NENPI 1669901765

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 268 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 47 manufacturers reported payments, led by AbbVie at 24.7% of the total. 2025 is the largest year on record at $1,365, 2.2 times the $615 reported in 2021. Among primary care clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,717in general payments, 2019–2025

Across 268 payments — averaging $17.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$456
  • Astellas Pharma US Inc$290
  • Amgen$255
  • Lilly USA, LLC$250
  • Novo Nordisk$242
  • plus $2K from 41 others

What the payments were for

  • Food & beverage$4,717100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,717 in reported general payments places this provider in the 90th percentile of 65 primary care providers in Nebraska.

See all primary care providers in Nebraska

Medicare billing

Part B allowed, 2024
$20,544
Medicare patients
132
Services billed
395

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide34$39,162
Duloxetine Hcl37$1,095
Bupropion XlBupropion Hcl28$1,007
Tamsulosin Hcl15$698
Losartan Potassium44$431
Pantoprazole Sodium24$406
Omeprazole43$401
Atorvastatin Calcium61$308
Rosuvastatin Calcium31$293
Amlodipine Besylate59$233
Lisinopril37$221
Sertraline Hcl19$197
Montelukast Sodium20$177
Gabapentin11$136
Potassium Chloride11$135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$250$39,16234 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 65 primary care providers in Nebraska.

Other primary care in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →